These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15800945)

  • 1. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
    Gibson RJ; Bowen JM; Keefe DM
    Int J Cancer; 2005 Sep; 116(3):464-70. PubMed ID: 15800945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.
    Gibson RJ; Stringer AM; Bowen JM; Logan RM; Yeoh AS; Burns J; Alvarez E; Keefe DM
    Cancer Biol Ther; 2007 Apr; 6(4):541-7. PubMed ID: 17457046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.
    Gibson RJ; Bowen JM; Inglis MR; Cummins AG; Keefe DM
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1095-100. PubMed ID: 12911669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.
    Stringer AM; Gibson RJ; Logan RM; Bowen JM; Yeoh AS; Burns J; Keefe DM
    Exp Biol Med (Maywood); 2007 Jan; 232(1):96-106. PubMed ID: 17202590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.
    Hu ZP; Yang XX; Chan SY; Xu AL; Duan W; Zhu YZ; Sheu FS; Boelsterli UA; Chan E; Zhang Q; Wang JC; Ee PL; Koh HL; Huang M; Zhou SF
    Toxicol Appl Pharmacol; 2006 Oct; 216(2):225-37. PubMed ID: 17015070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
    Gibson RJ; Bowen JM; Alvarez E; Finnie J; Keefe DM
    Chemotherapy; 2007; 53(5):360-9. PubMed ID: 17713326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan changes gene expression in the small intestine of the rat with breast cancer.
    Bowen JM; Gibson RJ; Cummins AG; Tyskin A; Keefe DM
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):337-48. PubMed ID: 16799812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.
    Logan RM; Gibson RJ; Bowen JM; Stringer AM; Sonis ST; Keefe DM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):33-41. PubMed ID: 17703303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Ikuno N; Soda H; Watanabe M; Oka M
    J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
    J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation.
    Dörr W; Reichel S; Spekl K
    Radiother Oncol; 2005 Apr; 75(1):99-105. PubMed ID: 15878107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of p53 in irinotecan-induced intestinal cell death and mucosal damage.
    Bowen JM; Gibson RJ; Stringer AM; Chan TW; Prabowo AS; Cummins AG; Keefe DM
    Anticancer Drugs; 2007 Feb; 18(2):197-210. PubMed ID: 17159606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
    Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1171-7. PubMed ID: 12145998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
    Waterhouse DN; Sutherland BW; Santos ND; Masin D; Osooly M; Strutt D; Ostlund C; Anantha M; Harasym N; Manisali I; Wehbe M; Bally MB; Webb MS
    Invest New Drugs; 2014 Dec; 32(6):1071-82. PubMed ID: 25064374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal toxicity or irinotecan.
    Hecht JR
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):72-8. PubMed ID: 9726096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy.
    Bowen JM; Gibson RJ; Tsykin A; Stringer AM; Logan RM; Keefe DM
    Int J Cancer; 2007 Oct; 121(8):1847-56. PubMed ID: 17594691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
    Cao S; Black JD; Troutt AB; Rustum YM
    Cancer Res; 1998 Aug; 58(15):3270-4. PubMed ID: 9699654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats].
    Takasuna K; Kasai Y; Kitano Y; Mori K; Kakihata K; Hirohashi M; Nomura M
    Nihon Yakurigaku Zasshi; 1995 Jun; 105(6):447-60. PubMed ID: 7557733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
    Valentí Moreno V; Brunet Vidal J; Manzano Alemany H; Salud Salvia A; Llobera Serentill M; Cabezas Montero I; Servitja Tormo S; Sopena Bert E; Gumà Padró J
    Clin Transl Oncol; 2006 Mar; 8(3):208-12. PubMed ID: 16648121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis.
    Bateman E; Weaver E; Klein G; Wignall A; Wozniak B; Plews E; Mayo B; White I; Keefe D
    Support Care Cancer; 2016 Jan; 24(1):377-385. PubMed ID: 26081596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.